Related Experiment Videos
Michael Schønemann Rand1, Pia Agnete Eiken2, Niklas Rye Jørgensen1,3
1Afdeling for Klinisk Biokemi, Københavns Universitetshospital - Rigshospitalet, Glostrup.
Ugeskrift for Laeger
|February 8, 2024
Summary
Bone turnover markers (BTM) quickly reflect changes in osteoporosis treatment, allowing timely adjustments. This review details using BTM for monitoring therapy, including during discontinuation of medications like alendronate and denosumab.
Area of Science:
- Endocrinology
- Bone Metabolism
- Pharmacology
Background:
- Bone turnover markers (BTM) offer rapid insights into anti-osteoporotic therapy response.
- Unlike bone mineral density, BTM changes allow for prompt clinical decision-making.
Approach:
- This review synthesizes current literature on BTM utility in managing osteoporosis treatment.
- It examines BTM's role in monitoring therapy initiation, adjustments, and discontinuation.
- Potential sources of error and pitfalls in BTM monitoring are also discussed.
Key Points:
- BTM are highly sensitive indicators of therapeutic intervention in osteoporosis.
- Rapid BTM changes facilitate timely adjustments to anti-osteoporotic drug regimens.
- Monitoring BTM is crucial during the discontinuation of therapies like alendronate and denosumab.
Conclusions:
- BTM provide a valuable tool for personalized osteoporosis treatment monitoring.
- Effective utilization of BTM can optimize therapeutic outcomes and patient management.
- Awareness of potential monitoring errors is essential for accurate interpretation of BTM results.